These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 27350294)

  • 21. Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation.
    Blankart KE; Vandoros S
    PLoS One; 2024; 19(5):e0301716. PubMed ID: 38696520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.
    Costa E; Santos C
    Eur J Health Econ; 2022 Dec; 23(9):1497-1518. PubMed ID: 35192093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pricing of drugs with heterogeneous health insurance coverage.
    Ferrara I; Missios P
    J Health Econ; 2012 Mar; 31(2):440-56. PubMed ID: 22484368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
    Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
    Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sending The Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less Than Generics?
    Dusetzina SB; Jazowski S; Cole A; Nguyen J
    Health Aff (Millwood); 2019 Jul; 38(7):1188-1194. PubMed ID: 31260351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal price regulations in international pharmaceutical markets with generic competition.
    Geng D; Saggi K
    J Health Econ; 2020 May; 71():102315. PubMed ID: 32273046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Competition and price among brand-name drugs in the same class: A systematic review of the evidence.
    Sarpatwari A; DiBello J; Zakarian M; Najafzadeh M; Kesselheim AS
    PLoS Med; 2019 Jul; 16(7):e1002872. PubMed ID: 31361747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
    Cheng N; Banerjee T; Qian J; Hansen RA
    J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What do pharmaceuticals really cost in the long run?
    Lakdawalla D; MacEwan JP; Dubois R; Westrich K; Berdud M; Towse A
    Am J Manag Care; 2017 Aug; 23(8):488-493. PubMed ID: 29087143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
    Spinks J; Chen G; Donovan L
    Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Tiered-Pricing Framework on Generic Entry in Canada.
    Zhang W; Sun H; Guh DP; Lynd LD; Hollis A; Grootendorst P; Anis AH
    Int J Health Policy Manag; 2022 Jun; 11(6):768-776. PubMed ID: 33233033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.